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Abstract
Cannabis has been integral to Eurasian civilization for millennia, but a century of prohibition has limited
investigation. With spreading legalization, science is pivoting to study the pharmacopeia of the cannabinoids, and a
thorough understanding of their biosynthesis is required to engineer strains with specific cannabinoid profiles. This
review surveys the biosynthesis and biochemistry of cannabinoids. The pathways and the enzymes’ mechanisms of
action are discussed as is the non-enzymatic decarboxylation of the cannabinoic acids. There are still many gaps in
our knowledge about the biosynthesis of the cannabinoids, especially for the minor components, and this review
highlights the tools and approaches that will be applied to generate an improved understanding and consequent
access to these potentially biomedically-relevant materials.
Keywords: Cannabinoid biosynthesis, Enzymatic transformation, C. sativa, Decarboxylation, Enzymatic mechanism

Main text
Historical context of cannabis science

Cannabis sativa L. (C. sativa, see glossary) has been a
staple of Eurasian culture. It is documented in Chinese
texts since before 2000 B.C. (Russo 2014); the Hindu
Atharvaveda, composed between 1500 and 1000 B.C.,
where it is revered as a sacred plant for ritual and ceremony (Russo 2005); and in New Kingdom Egyptian texts
dating to 1550 B.C. (Hallmann-Mikolajczak 2004).
Today, C. sativa is openly cultivated in more than 86
countries in Africa, the Americas, Asia, and Europe
(United Nations Office on Drugs and Crime 2005),
although the number is likely far higher. However, its
chemical characterization history is far briefer. Δ9-Tetrahydrocannabinol (THC), the primary psychoactive
component, was first isolated as an impure resin in
1942, when the structure was proposed (Wollner et al.
1942). In 1955, the first cannabinoid, cannabidiolic acid
(CBDA), was isolated in a pure form by Krejčí and
Šantavý. As recently as the late 1960s, it was considered
that the active principles of cannabis were an unidentified mixture of tetrahydrocannabinols (Mechoulam
1970). A crystallizable Δ9-THC derivative was prepared
in 1964, allowing ready access to the parent compound
* Correspondence: srondeau@uwindsor.ca; jtrant@uwindsor.ca
Department of Chemistry and Biochemistry, University of Windsor, 401
Sunset Avenue, Windsor, Ontario N9B 3P4, Canada

and ensuring that its structure and stereochemistry were
correctly assigned (Gaoni and Mechoulam 1964), with
CBD following soon after (Šantavý 1964). The literature
contains a series of foundational reviews covering the
chemistry of cannabinoids that contextualize the advancement of the field. Farnsworth’s 1969 review covers
botanical considerations of “marihuana,” the biological
evaluation of the plant and extracts, the known chemical
constituents, and the method for their identification
(Farnsworth 1969). Mechoulam’s 1970 influential review
on “marihuana chemistry” discussed nomenclature and
the chemical and the then-proposed biogenic synthesis
of cannabinoids (Mechoulam 1970). In 1975, Shoyama
et al. in their “biosynthesis of cannabinoid acids” discussed potential pathways used to synthesize cannabinoic acids from cannabigerolic acid (Shoyama et al.
1975). Turner and coauthors discuss the natural constituents and classes of metabolites of C. sativa in their
1980 review (Turner et al. 1980). However, the field has
progressed quickly in the decades since, rendering these
more of historical interest for the evolution of our understanding of cannabis. The most recent review on cannabis biosynthesis was authored by Flores-Sanchez and
Verpoorte in 2008, describing the biosynthesis of all
major secondary metabolites of C. sativa, e.g., flavonoids,
stilbenoids, terpenoids, alkaloids, lignanamides, and phenoic amides in addition to the cannabinoids (Flores-
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Sanchez and Verpoorte 2008). The field has evolved significantly in the 12 years since, especially in a complete
revaluation of the synthesis of olivetolic acid, the common precursor of the cannabinoids (Taura et al. 2009).
This review complements recent reviews on cannabinoid
structural biology (Shahbazi et al. 2020), cannabinoid
biological activity (Kinghorn et al. 2017), and an excellent short introductory review to cannabis science from
Reekie, Scott, and Kassiou (2017).
Cannabinoids are prenylated polyketides produced in
C. sativa (Taura et al. 2007a). More than 1600 chemical
compounds have been isolated from C. sativa, of which
over 180 are cannabinoids (Hanuš et al. 2016) that can
be classified into 11 structural families (Table S1) (Kinghorn et al. 2017; Taura et al. 2007a; Zirpel et al. 2018;
Merlin 2003). The most abundant cannabinoids (naturally present as their corresponding carboxylic acid) are
Δ9-tetrahydrocannabinol (Δ9-THC or THC, the main
psychoactive cannabinoid), cannabidiol (CBD), and cannabichromene (CBC); these are supplemented by other
classes archetyped by Δ8-trans-tetrahydrocannabinol
(Δ8-THC), cannabigerol (CBG), cannabinodiol (CBND),
cannabielsoin (CBE), cannabicyclol (CBL), cannabinol
(CBN), cannabitriol (CBT), and a miscellaneous group
(Kinghorn et al. 2017; Taura et al. 2007a; Merlin 2003;
Hampson et al. 1998; Lastres-Becker et al. 2005). In this
review, we will focus on the biosynthesis of major cannabinoids, i.e., THC, CBD and CBC, as the best studied,
both in terms of biosynthesis and pharmacological properties (Scheckel et al. 1968; Pertwee 2008; Pertwee 2005;
FDA, FDA and Cannabis: Research and Drug Approval
Process (n.d.); Petrosino et al. 2018; Lewis et al. 2017).
For our limited knowledge about the biosynthesis of
other cannabinoids, readers are referred elsewhere
(Ferioli et al. 2000; Husni et al. 2014; Radwan et al. 2015;
Wakshlag et al. 2020), with the caveat and encouragement that much work remains to be done in better understanding these biochemical pathways. Similarly,
readers interested in biotechnological synthesis of cannabinoids are referred to Luo et al. (2019), and to Leahy
and coworkers for a clever example of their chemical synthesis (Shultz et al. 2018). The biosynthesis of the cannabis
terpenes, present in small amounts in C. sativa (Hillig
2004; Fischedick et al. 2010; Booth et al. 2017; Booth and
Bohlmann 2019; Mudge et al. 2019; Zager et al. 2019) and
proposed to synergistically accentuate the pharmacological effects of cannabis consumption (Livingston et al.
2020; Russo 2011), is described elsewhere (Flores-Sanchez
and Verpoorte 2008; Page et al. 2006).
In C. sativa, cannabinoids are biosynthesized as phytoprotectants: in fresh biomass, 95% of the THC, CBD,
and CBC exist as their acidic parents: tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), and cannabichromenic acid (CBCA) (United Nations Office on
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Drugs and Crime 2005). These decarboxylate to the
more familiar forms during storage, upon heating, or
under alkaline conditions (United Nations Office on
Drugs and Crime 2005; Ghosh et al. 1940; Adams et al.
1940; Taura 2009). “Tetrahydrocannabinolic acid” or
“THCA” has been used vaguely and can refer to several
constitutional isomers, making physiological and
pharmacological profiling confusing (Moreno-Sanz
2016). In 1965, Korte et al. (1965) identified tetrahydrocannabinolcarboxylic acid (2-carboxy-THC, Fig. 1) as a
major component of hashish. In 1969, Mechoulam reported on a second THC acid isomer, the 4-carboxyTHC (Fig. 1), and named Korte’s THCA-A and his
THCA-B (Mechoulam et al. 1969). THCA-B was only
found in hashish samples with little to no THCA-A, and
its overall concentration was generally lower than 0.5
weight percent. Subsequent studies, however, were not
able to confirm the occurrence of THCA-B (De Zeeuw
et al. 1972). Therefore, in this review, we will use only
the term THCA and it always refers to THCA-A (2-carboxy-THC, Fig. 1) unless stated otherwise.
The Cannabis genus comprises three species defined
by their phytocannabinoid content: the low-THC C.
sativa L., the high Δ9-THC, C. indica Lam., and an
intermediate species, C. ruderalis Janisch (Mechoulam
1970; Hartsel et al. 2016; Appendino et al. 2011; Thomas
and ElSohly 2016); however, as the three species readily
interbreed and many existing cultivars are hybrids, a
monotypic classification, C. sativa, is gaining traction
with subdivisions into chemotypes rather than species
(Pellati et al. 2018). Varieties used for drug consumption,
characterized by a high content of Δ9-THC, are often
not morphologically distinguishable from low-THC
fiber-type varieties. Biosynthesis proceeds through the
same pathways in all species.
Cannabinoids are synthesized through a common
pathway in trichomes

The cannabinoids are biosynthesized in the glandular
trichomes, or “marijuana bud” of female flowers;
trichome-poor male flowers are typically very low in
cannabinoids (Livingston et al. 2020). Trichomes are also
present on bracts, leaves, and on the underside of the
anther lobes of male flowers (Mahlberg et al. 1980). Trichōma, Greek for “hair” (Figure S1a) (Kenneth 2018), are
classified as stalked, sessile, or bulbous (Figure S1 b-d)
(Hammond and Mahlberg 1973). Bulbous trichomes, the
smallest in size, produce limited cannabinoids; the other
two morphologies are responsible for almost all cannabinoid production. Sessile trichomes, supported by a
short stalk, have a globose head comprising a multicellular disc of secretory cells with a subcuticular metabolite
storage cavity (Hammond and Mahlberg 1977). Stalked
trichomes have a slightly larger globose head, rising
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Fig. 1 Structures of important Cannabis sativa cannabinoid classes: Δ9-tetrahydrocannabinol (Δ9-THC or THC) and its acidic counterparts (THCAA/THCA-B), tetrahydrocannabivarin (THCV), cannabidiol (CBD) and its acidic counterpart (CBDA), cannabigerol (CBG), cannabichromene (CBC), and
cannabinol (CBN)

several hundred microns above the epidermal surface
(Mahlberg and Kim 2004). The relative contribution of
sessile and stalked trichomes to cannabinoid production
remains unclear (Livingston et al. 2020).
The biosynthesis of cannabinoids remains incompletely understood at the molecular level (Fellermeier
and Zenk 1998). In brief, cannabinoids share a common
initial pathway: tetraketide synthase (TKS) (Kearsey et al.
2020), a type III polyketide synthase (PKS), catalyzes the
sequential condensation of hexanoyl-CoA with three
molecules of malonyl-CoA to yield 3,5,7-trioxododecaneoyl-CoA (Fig. 2a) (Taura et al. 2007b). This is cyclized
and aromatized, with the loss of Coenzyme A, by olivetolic acid cyclase (OAC), to olivetolic acid (OLA) (Gagne
et al. 2012). Aromatic prenyltransferase then inserts the
prenyl group at the highly nucleophilic 2-resorcinol position to provide cannabigerolic acid (CBGA) (Fellermeier
and Zenk 1998). This core intermediate then diverges to
provide the cannabinolic acids (THCA, CBDA, and
CBCA) that proceed to THC, CBD, and CBC by non-

enzymatic decarboxylation (Fig. 2a) (Flores-Sanchez and
Verpoorte 2009).
Olivetol synthase and olivetolic acid cyclase cooperate to
deliver the key intermediate

Olivetolic acid (OLA), forms the polyketide nucleus of
the cannabinoids (Taura et al. 2009; Gagne et al. 2012;
Tan et al. 2018). TKS was long thought to be solely responsible for OLA biosynthesis, with spontaneous
cyclization and aromatization occurring following the
addition of the third malonyl group as shown in the second step of Fig. 2a. However, while investigating the role
of the enzyme, Taura and co-workers used a cDNA, encoding olivetol synthase (OLS) cloned from C. sativa,
and found that their recombinant OLS did not produce
OLA, but only its decarboxylated form, olivetol (Fig. 2a)
(Taura et al. 2009). The authors also confirmed that
crude enzyme extracts of either flowers or early-growth
leaves, the two major cannabinoid-producing tissues of
C. sativa, also only provided olivetol (Taura et al. 2009;
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Fig. 2 Biosynthesis of cannabinoids. a Proposed cannabinoid biosynthetic pathway for Δ9-tetrahydrocannabinol (Δ9-THC), cannabidiol (CBD), and
cannabichromene (CBC) including by-product formation (pentyl diacetic lactone (PDAL), hexanoyl triacetic acid lactone (HTAL), and olivetol
shown in the dotted box) and highlighting the chemical conversion of CBD into THC, long thought to be the source of THC, but this conversion
does not occur in vivo. b Synthesis of geranyl pyrophosphate (GPP) from dimethylallyl pyrophosphate (DMAPP) and isopentenyl pyrophosphate
(IPP) catalyzed by geranyl pyrophosphate synthase

Dewick 2002). This strongly indicated that OLA biosynthesis is not dependent on OLS alone, but may involve
other enzymes; however, they considered that olivetol
may be an artifact of in vitro enzyme assays as olivetol is
not detected in C. sativa (Taura et al. 2009). This conundrum, OLA cannot be prepared in vitro, but the
in vitro product, olivetol, is not observed in vivo, has
since been resolved by evidence that the process requires
olivetolic acid cyclase (OAC), to conduct the intramolecular C2 → C7 aldol condensation without decarboxylation (Fig. 2a) (Gagne et al. 2012; Tan et al. 2018;
Kearsey et al. 2019). Kearsey et al. (2019) also confirmed
that, in the absence of OAC, a nonenzymatic C2 → C7

decarboxylative aldol condensation of the tetraketide
intermediate occurs forming olivetol instead of OLA
(Fig. 2a). Non-enzymatic background cyclization generates olivetol (Austin et al. 2004). The cyclase ensures
that the carboxylate survives biosynthesis.
This raises questions, however, as OLS does not interact with OAC, so the metabolite is not directly transferred, rather it must diffuse from one enzyme to the
other through the cytosol (Tan et al. 2018). Kearsey
et al. also investigated the crystal structure of TKS in the
presence of CoA (Fig. 3a) and also performed a
structure-guided mutagenesis study to investigate why
the tetraketide intermediate is released prior to OAC-
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Fig. 3 X-ray diffraction structures of three key enzymes implicated in cannabinoid biosynthesis. Key active site residues are highlighted in green, and interaction
diagrams, generated by the authors using the Schrödinger computational software suite (Maestro 2020), of a) tetrameric tetraketide synthase (TKS) from C. sativa in
complex with CoenzymeA (CoA, 6GW3), CoA is orange, with the four tetramers in red, orange, light green and cyan respectively (Kearsey et al. 2020); b) expansion
of the active site; c) Olivetolic acid cyclase (OAC) from C. sativa (5BO9) (Yang et al. 2016), the pentyl-binding pocket and its key residues are gray, olivetolic acid (OLA)
is orange, chain A is gray and chain B is in light orange; d) expansion of the active site, inverted; e) tetrahydrocannabinolic acid synthase (THCAS) from C. sativa
(3VTE) bound to flavin adenine dinucleotide (FAD) and without ligand. FAD is orange and the protein navy; and f) expansion of the active site (Shoyama et al. 2012)
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free cyclization (Kearsey et al. 2019). Noel and coworkers had suggested that an ‘aldol switch’ is necessary
to trigger tetraketide release, thereby enabling subsequent olivetolic acid production catalyzed by OAC
(Austin et al. 2004). However, Kearsey’s work does not
support the presence of a universal or predictable ‘aldol
switch’ consensus sequence. During the formation of
OLA, small quantities of pentyl diacetic lactone (PDAL)
and hexanoyl triacetic acid lactone (HTAL) are also
formed from non-enzymatic hydrolysis of the mono- and
di-malonylated intermediates respectively (Fig. 2a) (Taura
et al. 2007b; Gagne et al. 2012; Kearsey et al. 2019).
OLA is then converted into cannabigerolic acid
(CBGA) through the addition of geranyl pyrophosphate
(GPP) catalyzed by an aromatic prenyltransferase (APT)
(Lercker et al. 1992). GPP is synthesized by the condensation of isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) catalyzed by geranyl
pyrophosphate synthase (Fig. 2b) (Davis and Croteau
2000; Bohlmann and Gershenzon 2009 ). CBGA then
converts to THCA, CBDA, and CBCA (Fig. 2a) (Tan
et al. 2018; Shoyama et al. 2012).
In 1960s and 1970s, numerous plausible hypotheses
have been advanced regarding the biosynthesis of
THCA; however, they all were lacking experimental support. THCA was thought to arise from CBDA through
cyclization (Mechoulam 1970; Gaoni and Mechoulam
1964; Shoyama et al. 1975; Taura 2009). This was endorsed by Gaoni and Mechoulam, who, while establishing the structures of CBD and THC, boiled CBD with
0.05% v/v HCl in ethanol for 2 h, obtained a mixture of
THC and starting material (Fig. 2a) (Gaoni and Mechoulam 1964). However, the reaction conditions of the
transformation do differ from those present during natural biosynthesis in the plants; moreover, isomerase
activity, which would be necessarily responsible for the
conversion of CBDA into THCA, has never been
detected in any enzyme assays using crude C. sativa enzyme extracts. Current thinking suggests it comes from
CBGA instead by either tetrahydrocannabinolic acid synthase (THCAS) or cannabidiolic acid synthase (CBDAS),
both members of the p-cresol methyl-hydroxylase super
family (Taura et al. 2007b; Shoyama et al. 2012).
Structural and mechanistic nature of TKS, OAC, THCAS,
and CBDAS

The crystal structure of TKS has recently been released
by Kearsey et al. in 2019 (PDBID: 6GW3) (Fig. 3a)
(Kearsey et al. 2020). Two dimers are involved in the
asymmetric unit and there is no significant difference in
conformation between the four monomers. The resident
CoA forms five hydrogen bonds with residues CDS157,
LEU261, GLU299, LYS301, and ALA302 (Fig. 3a). The
active site is reasonably flexible to be compatible with a
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growing polyketide substrate. The CoA ligand sits with
the sulfur atom near the catalytic Cys157, which was oxidized to the sulfinic acid during crystallization. The putative catalytic water molecule is coordinated to both
Ser332, CSD157 and also interacts with other water
molecules.
Although the crystal structure of the full protein is unavailable, structural data from a truncated OAC and its
OAC–OLA binary complex, existing as a homodimer,
has been reported by Yang et al. (Fig. 3b) (Yang et al.
2016). OAC’s active-site cavity incorporates 18 residues;
nine of them form a long hydrophobic tunnel, the
pentyl-binding pocket, deep inside the active-site cavity
to selectively accommodate OLA’s pentyl chain (Fig. 3b),
ensuring OLA’s dihydroxy-benzoate moiety sits at the
entrance of the active-site cavity. OAC’s Tyr72 and
His78 form H-bond and π-π interactions respectively
with OLA, and also act as the acid and base catalysts to
assist cyclization.
Docking studies of the pentyl tetra-β-ketide CoA into
the OAC structure portended that His78 and Tyr72 are
involved in the catalytic mechanism. Yang et al. (2016)
proposed that His78 deprotonates the C2 carbon of 4.1,
and then protonates of the C7 oxygen in 4.2 to catalyze
the desired aldol cyclization to 4.3 (Fig. 4). Tyr72 activates the side chain of His78 (through deprotonation)
and the thioester carbonyl oxygen of the substrate
(through hydrogen bonding). No residues, metal ions, or
water molecules that may be involved in the thioester
bond cleavage and aromatization were observed in the
OAC–OA binary complex structure. This suggested that
OAC lacks both thioesterase and aromatase activities.
OAC consequently employs standard acid/base catalytic
chemistry for the formation of precursor 4.3, which then
dissociates from the enzyme and aromatizes and hydrolyzes to provide OLA (Yang et al. 2016).
In 1995, Taura and co-workers experimentally identified a new 76 kDa monomeric oxidoreductase, THCAS,
that converts CBGA into THCA (Taura 2009; Taura
et al. 1995) when CBGA was treated with an extract
from young leaves, high levels of THCA were produced.
The Taura group produced a cDNA sequence to simplify its study through heterologous expression, the first
enzyme involved in cannabis biosynthesis to be cloned
The parent gene THCAS consists of a 1635-nucleotide
open reading frame, encoding a 545-amino acid polypeptide, the first 28 of which constitute the signal peptide (Sirikantaramas et al. 2004). As an extension of this
effort, they developed a fermentation-friendly expression
system for THCAS, a requirement for the biotechnological production of Δ9-THC (Sirikantaramas et al.
2004; Taura et al. 2007c). This vision has been fully realized by the recent work of Keasling that allows for the
access of cannabinoids from yeast (Luo et al. 2019).
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Fig. 4 Proposed mechanism for the formation of olivetolic acid (OLA) by olivetolic acid cyclase (OAC)

Fig. 5 Reaction mechanism for the conversion of cannabigerolic acid (CBGA) into tetrahydrocannabinolic acid (THCA) proposed by Taura and
cowerkers (2019). a Covalently incorporated flavin adenine dinucleotide (FAD) in black, b THCA synthase pathway is shown in green, and c
cannabidiolic acid (CBDA) synthase pathway is shown in purple; CBDA and THCA in red. The red box represents the active site of the enzyme
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In 2012 Kuroki and Morimoto reported an X-ray
crystal structure of THCA synthase that provides significant mechanistic insight: the active site locks FAD in
place through two covalent bonds with His114 and
Cys176 (Fig. 3c) (Shoyama et al. 2012). This covalent
immobilization is supported by a series of key H-bonds
with 10 additional residues, making FAD a permanent
feature of the enzyme; this ligand, along the Cys37Cys99 disulfide bridge, drives proper folding of the rest
of the active site. These combine to immobilize CBGA
to facilitate hydride transfer to FAD setting up a formal
enantiospecific hetero Diels-Alder reaction (Zirpel
2018), although the mechanism likely proceeds through
a standard carbocation ionic pathway (Fig. 5a).
CBDAS is a 517-amino acid polypeptide with a theoretical mass of 59 kDa, although no crystal structure has
been obtained (Taura et al. 2007b; Lercker et al. 1992). Experimentally, it has been detected as a 74 kDa protein,
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possibly the result of posttranslational N-glycosylation of
seven Asn residues (Taura et al. 2007b; Taura et al. 1996).
Like THCAS, CBDAS is also a flavinated enzyme; His114
and Cys176 are the most likely FAD-binding sites based
on analogy with THCAS. Morimoto has proposed that the
mechanism of the two enzymes is likely very similar
(Taura et al. 2007b). The Morimoto group has proposed
that the significant difference between their primary mode
of action is in the proton transfer step: CBDAS abstracts a
proton from the terminal methyl group of CBGA instead
of from the hydroxyl group targeted by THCAS, this
change in regioselectivity determines the cyclization
(Fig. 5b, c) (Taura et al. 2007b; Taura et al. 2019).
Despite this minor difference in mechanism, THCAS
and CBDAS have 84% sequence identity (Taura et al.
2007b), with mutations at key active site residues likely
explaining their differing cyclization specificity (Fig. 6a)
(Onofri et al. 2015). they both generate eight different

Fig. 6 Comparison of cannabidiolic acid synthase (CBDAS) and tetrahydrocannabinolic acid synthase (THCAS) and the metabolism of
cannabinoids. a Homology model of CBDAS developed from THCAS (3VTE); residues conserved from THCAS are purple while variant residues are
cyan, sequence insertions are red, and FAD is green; b active site of these enzymes highlighted with a cartoon showing conversion to
tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA) and cannabichromenic acid (CBCA) from cannabigerolic acid (CBGA); c
experimentally demonstrated oxidation (ox) and isomerization (is) reactions and metabolic fates (encircled) for Δ9-THCA and
Δ9-Tetrahydrocannabinol (Δ9-THC)
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products, although in different ratios. Whereas THCAS
produces CBDA and CBCA as minor products, CBDAS
produces small amounts of THCA and CBCA in
addition to CBDA (Fig. 6b) (Zirpel et al. 2018). This
similarity can be exploited and a simple point mutation,
A414V in THCAS yields an analog with threefold higher
catalytic activity for the production of CBDA than
THCAS, but also with 19-fold higher production of
THCA and a broadened pH spectrum for the production
of CBDA, THCA, and CBCA (Zirpel et al. 2018).
Recently the sequence of CBCAS was reported by Page
and Stout (2019). The sequence identity between CBDAS
and THCAS is near identity: 96% (van Bakel et al. 2011).
Morimoto had previously purified the enzyme to apparent
homogeneity, but this sequence is not yet available in public databases (Morimoto et al. 1998). CBCAS was isolated
and partially purified from young leaves of C. sativa
(Morimoto et al. 1998; Morimoto et al. 1997). In contrast
to CBDAS and THCAS, CBCAS seems to be homodimer
with a determined native molecular mass of 136 kDa and
a maximum activity at pH 6.5. A molecular mass of 71
kDa was estimated for the monomers using SDS-PAGE.
According to kinetic data, CBCAS has a higher affinity for
CBGA than THCAS and CBCAS (Morimoto et al. 1998).
CBCA and its neutral form CBC are both racemic. Studies
by Morimoto suggested that both enantiomers of CBCA
are formed by a CBCAS catalyzed reaction in a molar ratio
of 5:1 (Morimoto et al. 1997). But it is still unknown
which of the two isomers is the major product (Taura
et al. 2007a; Morimoto et al. 1997; Gaoni and Mechoulam
1971). Much work remains to be done to better understand this enzyme.
Decarboxylation of cannabinoid acids

The neutral cannabinoids, like Δ9-THC and CBD do not
occur at significant concentrations in the plants but are
readily accessed by nonenzymatic thermal decarboxylation when exposed to light or heat via smoking or baking (Tan et al. 2018). To characterize decarboxylation,
sensitive analytical methods are needed to quantify, in
real-time, the concentrations of both acids and neutral
cannabinoids in their complex matrix (Wang et al.
2016). Temperature and heating duration are very important: over-heating directly decomposes cannabinoids
and prolonged reaction times induce side reactions including over-oxidation, decreasing the yield and increasing the impurity profile (Fig. 6c). Chemical analyses are
usually reported as the sum of the acidic and neutral
forms of the cannabinoids; furthermore, THC levels are
reported as a combination of THC and CBN levels as
Δ9-THCA and Δ9-THC themselves readily oxidize respectively to CBNA and cannabinol (CBN, Fig. 6c) with
heat, oxygen, and light (Moreno-Sanz 2016; Pellati et al.,
2018; Dussy et al. 2005). These levels are measured
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primarily using either gas or liquid chromatography (GC
and LC) (Wang et al. 2016). Based on the work of many
analytical studies using gas and liquid chromatography
over recent years (for a detailed review of the contributions of various authors, please see the SI, Figures S2
and S3), the current proposed mechanism for thermal
decarboxylation invokes an intramolecular hydrogen
bond with the ortho-phenol (Figure S4) and appears to
be a commonality for this series of 2-hydroxybenzoic
acids (Perrotin-Brunel et al. 2011).
Stability and derivatization of THC and THCA

As discussed, Δ9-THCA and Δ9-THC readily oxidize
into CBNA and CBN in the presence of oxygen and light
during thermal decarboxylation or even just upon aging
(Fig. 6c) (Moreno-Sanz 2016; Pellati et al., 2018; Dussy
et al. 2005) in the same way, during storage or during
decarboxylation, Δ9-THC can also oxidize into an isomer known as Δ8-THC, which is an artifact of the aging
process (Pellati et al., 2018). As decarboxylation is only
partial, THCA can be found, together with Δ9-THC, in
the oral fluid, serum, and urine of cannabis consumers
(Dussy et al. 2005; Jung et al. 2007; Moore et al. 2007).
This can be used forensically, as THCA does not convert
to Δ9-THC in vivo, displaying its own metabolic and
elimination pathways (Fig. 6c); consequently, the presence of THCA distinguishes between the use of plantbased cannabis and prescribed synthetic Δ9-THC, e.g.,
Marinol® (Jung et al. 2009; Raikos et al. 2014). Although
still relevant in jurisdictions practicing prohibition, this
is likely to become far less important as legalization
spreads.
In 1970, Agurell et al. confirmed the existence of
acid metabolites of Δ9-THC (Agurell et al. 1970). The
authors injected radiolabeled Δ9-THC into rabbits;
urine analysis confirmed the presence of 11-nor-9carboxy-delta 9-THC (THC-COOH, Fig. 6c). THCCOOH produces no psychotropic responses in
humans, and is further metabolized into glucuronide
conjugates (Wall and Perez-Reyes 1981). THC-COOH
does not elicit cannabimimetic behaviors in mice and
shows no affinity for the CB1 receptor (Martin et al.
1995). A related carboxylate derivative of THC (carboxylic acid analog of Δ9-THC, Fig. 6c) was isolated
from high potency C. sativa plants (Husni et al.
2014). This compound, improperly referred to as Δ9THC, displayed low affinity (in the mM range) for
both CB1 and CB2 receptors. This is in agreement
with a previous report, where Δ9-THCA was synthesized as part of a structure–activity relationship study
conducted on the C-1 position of Δ9-THC (Burdick
et al. 2010). The analysis of the metabolites of the
other cannabinoids has not been extensively studied
and could prove fruitful; however, the low affinity of
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carboxylated cannabinoids for their receptors likely
implies that they will be inactive on this pathway.
Concluding remarks and future perspectives

Although much effort has been expended to investigate the biosynthesis of cannabinoids, and their
mechanisms of decarboxylation and metabolism,
much remain unclear. We still lack structural data for
many of the enzymes involved, and we have little information about how the approximately 200 different
cannabinoids are each prepared. At a larger scale, the
relative role and gene expression profile of the different trichomes in the plant is not understood. Research into the physiological activity of cannabis has
been largely restricted to THC and CBD, but there is
clear evidence that some of the effects arise from the
other cannabinoids. As their promise for therapeutics
becomes ever clearer, we will need a better understanding of these pathways so that we can re-engineer
them, either in the plant or a recombinant vector, for
their selective production. Remarkable progress has
been achieved in the last two decades in cannabinoid
natural product chemistry, but much work remains to
be done to attain the goal of producing chosen cannabinoids in high quantities and purity for both
therapeutic and recreational purposes.
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